Understanding APC | malecare.org

Dr. S. Meyers Posts a Video About Intermittent vs. Continuous Hormone Therapy for Men with Prostate Cancer and Bone Metastasis

On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not [...]

By Malecare|2020-02-04T10:37:34-05:00June 13th, 2012|Advanced Prostate Cancer, ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Metastases, Uncategorized, Understanding APC|0 Comments

From ASCO: Liver Metastases And Its Prognostic Significance In Men With Metastatic Prostate Cancer

According to data presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655) the presences of liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC). William Kevin Kelly, DO, Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson, and colleagues from the [...]

By Malecare|2017-10-19T10:51:06-04:00June 11th, 2012|Advanced Prostate Cancer, ASCO, biomarkers, Clinical Trials, Clinical Trials, General Information, Metastases, Uncategorized, Understanding APC|0 Comments

Towards A Biomarker To Predict Survival in Advanced Prostate Cancer

According to the results of a study published in the Journal of Clinical Oncology a bone scan index (BSI) can assess response to treatment and predict survival in metastatic hormone-refractory prostate cancer. Men who have castrate resistant or metastatic hormone-refractory prostate cancer that no longer responds to hormonal therapy and has spread to distant sites [...]

By Malecare|2017-10-19T10:51:06-04:00June 8th, 2012|Advanced Prostate Cancer, biomarkers, Bone Metastases, Bone Mineral Density, Metastases, On The Horizon, Prostate Ponderings, Research, Uncategorized, Understanding APC|0 Comments

My Current Personal Take on Intermittent Hormone Therapy for Prostate Cancer

On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy is not as good as continuous hormone therapy with regard to [...]

By Malecare|2017-10-19T10:51:06-04:00June 7th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Me, Uncategorized, Understanding APC|8 Comments

The Anti-Depressant Cymbalta Can Help Manage Peripheral Neuropathy From Chemotherapy

In a study presented at ASCO, researchers found that the drug duloxetine (Cymbalta) can help to treat peripheral neuropathy, a painful side effect of chemotherapy using taxanes. Taxotere, the chemotherapy drug used to treat castrate resistant, advanced prostate cancer is a taxane. Peripheral neuropathy occurs when nerves in the body's peripheral nervous system (outside the [...]

By Malecare|2012-06-06T08:53:56-04:00June 6th, 2012|Advanced Prostate Cancer, ASCO, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, peripheral neuropathy, Uncategorized, Understanding APC|0 Comments